Home > Publications database > Celebrating Ulrik Ringborg: Multi-Omics-Based Patient Stratification for Precision Cancer Treatment. > print

001     301718
005     20250627115716.0
024 7 _ |a 10.3390/biom15050693
|2 doi
024 7 _ |a pmid:40427586
|2 pmid
037 _ _ |a DKFZ-2025-01110
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Teleanu, Maria-Veronica
|0 P:(DE-He78)4e4e534b615747750de8b9a7afdd8f56
|b 0
|e First author
|u dkfz
245 _ _ |a Celebrating Ulrik Ringborg: Multi-Omics-Based Patient Stratification for Precision Cancer Treatment.
260 _ _ |a Basel
|c 2025
|b MDPI
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1751018213_5798
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:B340#LA:B340# / 2025 May 10;15(5):693
520 _ _ |a Precision oncology is becoming a mainstay in the standard of care for cancer patients. Recent technological advancements have significantly lowered the cost of various tumor profiling approaches, broadening the reach of molecular diagnostics and improving patient access to precision oncology. In parallel, drug development and discovery pipelines continue to evolve, driving targeted therapeutic options forward. Yet, not all patients harboring actionable molecular alterations respond to these interventions, and existing therapies do not cover the entire spectrum of potential molecular targets. In this review, we examine the current suite of omics technologies employed in clinical settings and underscore their roles in deepening our understanding of tumor biology and optimizing patient stratification for targeted treatments. We also highlight relevant precision oncology trials and share our own experiences using multi-omics data within a molecular tumor board framework. Finally, we discuss areas for future exploration aimed at propelling precision oncology to new heights.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a molecular profiling
|2 Other
650 _ 7 |a patient stratification
|2 Other
650 _ 7 |a precision oncology
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Precision Medicine: methods
|2 MeSH
650 _ 2 |a Neoplasms: genetics
|2 MeSH
650 _ 2 |a Neoplasms: metabolism
|2 MeSH
650 _ 2 |a Neoplasms: drug therapy
|2 MeSH
650 _ 2 |a Neoplasms: therapy
|2 MeSH
650 _ 2 |a Genomics: methods
|2 MeSH
650 _ 2 |a Proteomics: methods
|2 MeSH
650 _ 2 |a Multiomics
|2 MeSH
700 1 _ |a Schneider, Annika
|0 P:(DE-He78)01467978dd6fe4c28888cc8a5109cd35
|b 1
|u dkfz
700 1 _ |a Ball, Claudia
|0 P:(DE-He78)7a10ea1b9b2872da9f375002c44ddfce
|b 2
700 1 _ |a Leber, Mathias Felix
|0 P:(DE-He78)1401445b374879f90e840ca2e6a96bac
|b 3
|u dkfz
700 1 _ |a Stange, Christoph
|0 P:(DE-He78)5c7b30aaeb7a74a0dee50c5cc776b143
|b 4
|u dkfz
700 1 _ |a Krieghoff-Henning, Eva
|0 P:(DE-He78)8e2078af783ff2be822e7799c43bc86a
|b 5
|u dkfz
700 1 _ |a Beck, Katja
|0 P:(DE-He78)f6b238ac374345c55706521c4f435779
|b 6
700 1 _ |a Heilig, Christoph E
|0 P:(DE-He78)42b6114cd48e033299b2b6ef4bf56cc6
|b 7
|u dkfz
700 1 _ |a Kreutzfeldt, Simon
|0 P:(DE-He78)e5972dddc3c8d1412db29ba54fed83ba
|b 8
700 1 _ |a Kuster, Bernhard
|0 0000-0002-9094-1677
|b 9
700 1 _ |a Lipka, Daniel
|0 P:(DE-He78)c403a040c97f91902a7d31b93859f9fc
|b 10
|u dkfz
700 1 _ |a Fröhling, Stefan
|0 P:(DE-He78)f0144d171d26dbedb67c9db1df35629d
|b 11
|e Last author
773 _ _ |a 10.3390/biom15050693
|g Vol. 15, no. 5, p. 693 -
|0 PERI:(DE-600)2701262-1
|n 5
|p 693
|t Biomolecules
|v 15
|y 2025
|x 2218-273X
909 C O |p VDB
|o oai:inrepo02.dkfz.de:301718
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)4e4e534b615747750de8b9a7afdd8f56
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)01467978dd6fe4c28888cc8a5109cd35
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)7a10ea1b9b2872da9f375002c44ddfce
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)1401445b374879f90e840ca2e6a96bac
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)5c7b30aaeb7a74a0dee50c5cc776b143
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)8e2078af783ff2be822e7799c43bc86a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)f6b238ac374345c55706521c4f435779
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)42b6114cd48e033299b2b6ef4bf56cc6
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)e5972dddc3c8d1412db29ba54fed83ba
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 0000-0002-9094-1677
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)c403a040c97f91902a7d31b93859f9fc
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)f0144d171d26dbedb67c9db1df35629d
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2025
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BIOMOLECULES : 2022
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-04-10T15:31:02Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-04-10T15:31:02Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2024-04-10T15:31:02Z
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2024-04-10T15:31:02Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-11
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-11
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-11
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b BIOMOLECULES : 2022
|d 2024-12-11
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-11
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-11
920 2 _ |0 I:(DE-He78)B340-20160331
|k B340
|l Translationale Medizinische Onkologie
|x 0
920 1 _ |0 I:(DE-He78)B340-20160331
|k B340
|l Translationale Medizinische Onkologie
|x 0
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 1
920 1 _ |0 I:(DE-He78)MU01-20160331
|k MU01
|l DKTK Koordinierungsstelle München
|x 2
920 1 _ |0 I:(DE-He78)DD01-20160331
|k DD01
|l DKTK Koordinierungsstelle Dresden
|x 3
920 1 _ |0 I:(DE-He78)D490-20160331
|k D490
|l KKE Virotherapie
|x 4
920 1 _ |0 I:(DE-He78)A420-20160331
|k A420
|l Personalisierte Medizinische Onkologie
|x 5
920 0 _ |0 I:(DE-He78)B340-20160331
|k B340
|l Translationale Medizinische Onkologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B340-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a I:(DE-He78)MU01-20160331
980 _ _ |a I:(DE-He78)DD01-20160331
980 _ _ |a I:(DE-He78)D490-20160331
980 _ _ |a I:(DE-He78)A420-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21